[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ahmed Karam Helmy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100617626",false,"NCT07321067","Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes","ICIs","Inclusion Criteria:\n\n* Adults (≥18 years) with radiologically or histologically confirmed advanced HCC\n* Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab).\n* Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .\n\nExclusion Criteria:\n\n* Child-Pugh C liver function.\n* Prior liver transplantation.\n* patients with concurrent malignancies other than HCC.\n* Active autoimmune disease requiring systemic immunosuppression.","ALL","18 Years",{"count":18,"type":19},75,"ESTIMATED","12 Months","OBSERVATIONAL","the Objectives of this study are:\n\n• Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors.\n\nthe main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.",[24],"Advanced Hepatocellular Carcinoma (HCC)",[26,27],"advanced hepatocellular carcinoma","immune checkpoint inhibitors","NOT_YET_RECRUITING","2025-12-21",{"date":31,"type":32},"2026-01-06","ACTUAL",{"date":34,"type":19},"2026-01-01",{"date":36,"type":19},"2027-11-01",{"name":38,"class":39},"Ahmed Karam Helmy","OTHER",2,""]